Haleon plc (LON:HLN) Insider Blathnaid Bergin Acquires 6,145 Shares

Haleon plc (LON:HLN - Get Free Report) insider Blathnaid Bergin bought 6,145 shares of the stock in a transaction that occurred on Friday, May 16th. The shares were purchased at an average cost of GBX 404 ($5.47) per share, for a total transaction of £24,825.80 ($33,607.42).

Haleon Trading Up 0.0%

HLN traded up GBX 0.10 ($0.00) during trading on Friday, reaching GBX 411.60 ($5.57). The company had a trading volume of 14,350,740 shares, compared to its average volume of 26,490,453. The firm's 50-day simple moving average is GBX 387.91 and its 200 day simple moving average is GBX 382.50. The company has a market cap of £37.15 billion, a price-to-earnings ratio of 34.62, a PEG ratio of 1.49 and a beta of 0.19. Haleon plc has a 12-month low of GBX 319.84 ($4.33) and a 12-month high of GBX 417.70 ($5.65). The company has a debt-to-equity ratio of 53.36, a quick ratio of 0.93 and a current ratio of 0.84.

Haleon (LON:HLN - Get Free Report) last announced its quarterly earnings data on Friday, February 28th. The company reported GBX 15.80 ($0.21) EPS for the quarter. Haleon had a return on equity of 6.54% and a net margin of 9.66%. Equities research analysts anticipate that Haleon plc will post 19.5033282 earnings per share for the current year.

Haleon Increases Dividend

The firm also recently disclosed a dividend, which will be paid on Thursday, June 5th. Shareholders of record on Thursday, April 24th will be given a dividend of GBX 4.60 ($0.06) per share. The ex-dividend date is Thursday, April 24th. This is a positive change from Haleon's previous dividend of $2.00. This represents a yield of 1.18%. Haleon's dividend payout ratio (DPR) is presently 50.46%.

Analyst Upgrades and Downgrades

Separately, Berenberg Bank lifted their price target on Haleon from GBX 456 ($6.17) to GBX 457 ($6.19) and gave the stock a "buy" rating in a research note on Friday, February 28th.

About Haleon

Haleon LSE / NYSE: HLN is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges. Haleon's portfolio spans five global categories including Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health and Digestive Health and other.